The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of TD-1211 in healthy subjects and activity in subjects with opioid-induced constipation (OIC).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
102
Clinical Research Unit
Pasadena, California, United States
Clinical Research Unit
San Antonio, Texas, United States
Clinical Research Unit
Salt Lake City, Utah, United States
Safety and tolerability in healthy subjects and activity in subjects with opioid-induced constipation
Time frame: Daily pre and post dose assessments throughout the duration of the study period
Evaluation of the multiple dose pharmacokinetics of TD-1211 following oral administration
Time frame: Daily pre and post dose assessments throughout the duration of the study period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Dose Level 4
Ascending doses
Ascending doses
Ascending doses
Ascending doses
Ascending doses
Ascending doses